OncoMatch/Clinical Trials/NCT05862012
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Is NCT05862012 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including ISB 2001 and ISB 2001 for relapsed/refractory multiple myeloma.
Treatment: ISB 2001 · ISB 2001 — This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Standford Cancer Institute · Palo Alto, California
- University of Chicago Medical Center · Chicago, Illinois
- Montefiore Medical Center · The Bronx, New York
- University of North Carolina · Chapel Hill, North Carolina
- Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05862012 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages